Veradermics to Hold Conference Call to Discuss Topline Results from Phase 3 ‘304’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
Business Wire•18/10/2026•18:00 ET
1
Key Highlights
- ➤Veradermics will report Study ‘304’ Phase 3 topline results October 19, 2026
- ➤Study ‘304’ enrolled 536 men with mild-to-moderate pattern hair loss
- ➤VDPHL01 is an 8.5 mg extended-release oral minoxidil formulation
- ➤Registration-directed program enrolled more than 1,600 adult men and women
- ➤VDPHL01 could become the only FDA-approved oral non-hormonal treatment for pattern hair loss
Veradermics to Hold Conference Call to Discuss Topline Results from Phase 3 ‘304’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
Conference call will take place on Monday, October 19, 2026, at 8:00 am ET
Get started
Create a free account to read the full story.